Non-degradable swellable polymers as materials for biomedical devices
Non-degradable swellable polymer hydrogels with alternating quaternary and secondary carbon atoms address the degradation issues of existing intraocular shunts by providing a stable, expandable solution for managing glaucoma and ocular hypertension.
Patent Information
- Application Number
- JP2021571853
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-03
- Filing Date
- 2020-06-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-06-02
AI Technical Summary
Existing intraocular shunts made from materials like porcine gelatin degrade over time due to tissue growth and hydrolysis, leading to inflammation and fragility, necessitating materials that resist skeletal degradation and maintain biostability for extended periods.
Development of non-degradable swellable polymer hydrogels with alternating quaternary and secondary carbon atoms in the backbone, featuring hydrophobic and hydrophilic side groups, which swell upon hydration to maintain structural integrity and stability within the eye.
The hydrogels provide a stable, non-degradable intraocular shunt that expands in place, reducing the need for additional treatments and maintaining functionality without moving or breaking, thus effectively managing glaucoma and ocular hypertension.
Smart Images

Figure 0007584452000007 
Figure 0007584452000008 
Figure 0007584452000009
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 856,447, filed June 3, 2019, and entitled “Non-Degrading Swellable Polymers as Materials for Biomedical Devices,” which is hereby incorporated by reference in its entirety.
[0002] Disclosure Fields The present disclosure relates to medical devices, such as intraocular shunts, made from materials that include non-degradable swellable polymer hydrogels, and methods of making the same. [Background technology]
[0003] background Intraocular shunts are used to treat glaucoma. Shunts can be introduced ab interno (introduced into the anterior chamber) or ab externo (through the conjunctiva or sclera) to shunt fluid from the anterior chamber under the conjunctiva or under Tenon's capsule. Regardless of the location of the outflow, either route results in a subconjunctival pustule. The shunt can be inserted into place using a needle-like inserter and is designed to inflate in place to create a seal between the needle track and the shunt, directing flow into the lumen of the device. The lumen is designed as a flow resistor or flow restrictor to prevent hypotony (bulging of the eye) and hypertrophy (excessive pressure within the eye).
[0004] A typical glaucoma shunt that swells into place is a simple tube, often made from porcine gelatin cross-linked with glutaraldehyde. The problem with shunts made from collagen is that tissue can grow into the walls of the proteinaceous shunt, and macrophages and water can oxidize and hydrolyze the proteinaceous shunt, producing by-products, inducing inflammation, making it brittle and fragile, and breaking off when manipulated. Eventually the shunt becomes completely overgrown and fails, necessitating further treatment to lower intraocular pressure (IOP) to halt the progression of glaucoma and prevent vision loss.
[0005] Thus, there is a need for ocular shunts and materials for manufacturing same that do not undergo scaffold degradation and survive in the desired anatomical location for placement of the ocular shunt. Also, more broadly, there is a need for materials for additional types of implantable medical devices that are required to swell upon implantation and remain biostable over extended periods of time without significant degradation. Summary of the Invention
[0006] overview In a first aspect, disclosed herein is an ocular shunt formed from a material comprising a polymer, the polymer being formed from the reaction product of a first monomer comprising a first side group, a second monomer comprising a second side group, and a crosslinker. In certain embodiments, the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group. In certain embodiments, the ocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter. In certain embodiments, the polymer comprises a backbone in which a majority of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 50% to about 100% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the first side group is a hydrophobic group and the second side group is a hydrophilic group. In certain embodiments, the hydrophilic group is an ionizable or ionizable group. In certain embodiments, the hydrophilic group is a non-ionizable hydrophilic group. In certain embodiments, the first and second monomers are acrylates or acrylamides. In certain embodiments, the first monomer is 2-hydroxyethyl methacrylate (HEMA). In certain embodiments, the second monomer is methacrylic acid (MAA). In certain embodiments, the crosslinker is tetraethylene glycol dimethyl acrylate (TEGDMA). In certain embodiments, the polymer is a hydrogel. In certain embodiments, the second diameter is about 20% to about 200% larger than the first diameter. In certain embodiments, the second diameter is about 100% larger than the first diameter.
[0007] In a further aspect, disclosed herein is an ocular shunt formed from a material comprising a non-degradable swellable polymer, the polymer comprising a first side group comprising a hydrophobic group or a non-ionized hydrophilic group and a second side group comprising an ionized group or an ionized hydrophilic group or a non-ionized hydrophilic group. In certain embodiments, the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group. In certain embodiments, the diameter of the ocular shunt increases upon hydration of the ocular shunt from a dehydrated state to a hydrated state. In certain embodiments, the hydrophobic group is selected from the group consisting of alkyl, aryl, halo, alkylaryl, and alkoxy. In certain embodiments, the ionized or ionizable group is selected from the group consisting of carboxylic acid, amine, ammonium salt, and sulfonic acid.
[0008] In another aspect, disclosed herein is a compound having the formula: an ocular shunt formed from a material comprising a non-degradable swellable polymer having a molecular weight of 1000 to 15000; TIFF0007584452000001.tif3168, wherein R, R' and R'' each comprise a terminal alkyl, aryl, halo, alkylaryl, or alkoxy group, R''' is an amine, ammonium salt, carboxylic acid, or sulfonic acid, and the ratio of m:n is from about 99.99:0.01 to about 90:10. In certain embodiments, the ocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0009] In a further aspect, disclosed herein is a method of treating glaucoma or ocular hypertension in a subject in need thereof, comprising introducing into an eye of the subject an ocular shunt formed from a material comprising a polymer, the polymer formed from the reaction product of a first monomer comprising a first side group, a second monomer comprising a second side group, and a crosslinker, where the second side group is more hydrophilic than the first side group, and the ocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0010] In a further aspect, disclosed herein is the use of an ocular shunt for the treatment of glaucoma or ocular hypertension, the ocular shunt being formed from a material comprising a polymer, the polymer being formed from the reaction product of a first monomer comprising a first side group, a second monomer comprising a second side group, and a crosslinker, where the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group, and the ocular shunt having a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0011] In a further aspect, disclosed herein is the use of an ocular shunt for implantation in a subject in need of treatment, the ocular shunt formed from a material comprising a polymer, the polymer formed from the reaction product of a first monomer comprising a first side group, a second monomer comprising a second side group, and a crosslinker, where the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group, and the ocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter. [Brief description of the drawings]
[0012] BRIEF DESCRIPTION OF THE DRAWINGS The following detailed description of certain embodiments of the present disclosure will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present disclosure, certain embodiments are shown in the drawings. It should be understood, however, that the disclosure is not limited to the precise arrangements and manners of the embodiments shown in the drawings.
[0013] FIG. 1A illustrates an intraocular shunt in a dehydrated state according to an embodiment of the present disclosure.
[0014] FIG. 1B illustrates an intraocular shunt in a hydrated state according to one embodiment of the present disclosure.
[0015] FIG. 2 illustrates an intraocular shunt inserted into the lumen of a needle according to one embodiment of the present disclosure.
[0016] FIG. 3 illustrates an intraocular shunt placed in hydrated tissue according to one embodiment of the present disclosure.
[0017] FIG. 4 is a graph of water content and swelling volume of a gel according to an embodiment of the present disclosure.
[0018] FIG. 5 shows a pHEMA tube in a hydrated state (top) and a dehydrated state (bottom) according to one embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Detailed Description of the Invention The present disclosure relates to a family of hydrogels for use as materials in intraocular shunts, e.g., glaucoma shunts. In certain embodiments, the hydrogels do not undergo backbone degradation and survive in the anatomical location desired for the glaucoma shunt. The hydrogels can be used to make devices, such as implantable devices. The hydrogels of the present disclosure and devices made therefrom can advantageously swell when exposed to certain fluids, i.e., biological fluids; however, in contrast to known devices, the hydrogels and devices of the present disclosure do not degrade or become brittle when exposed to fluids, and are therefore suitable as implantable devices in subjects. In certain embodiments, the hydrogels comprise substantially aliphatic polymers, i.e., polymers that have substantially no double bonds in the polymer backbone. In certain embodiments, the hydrogels comprise fully aliphatic polymers, i.e., polymers that have no double bonds in the polymer backbone. In certain embodiments, the aliphatic polymers do not undergo degradation when exposed to fluids, i.e., biological fluids. In certain embodiments, the aliphatic polymers are selected from the group consisting of S, S-, S-α, S-β ... N1 hydrolysis reactions and therefore undergo little or no degradation when implanted in a subject. Thus, in certain embodiments, the hydrogel swells upon hydration but does not degrade when inserted into a patient's eye. In certain embodiments, the hydrogel structure comprises features that promote swelling upon hydration and features that limit degradation. One non-limiting advantage of the present disclosure is the ability to fabricate devices, e.g., intraocular shunts, that swell into place when inserted into the eye, thereby eliminating the need for fins or barbs to keep the device from migrating in and out of the eye. Additionally, devices made from the materials disclosed herein can be placed in the eye in both ab-interno or ab-externo ways. Importantly, simple ab-externo implantation can be performed in a physician's office rather than in an operating room, reducing the burden on both the patient and physician. Another non-limiting advantage of the hydrogels (and devices made therefrom) of the present disclosure is the ability to fabricate devices to the appropriate specifications to fit through a particular gauge needle lumen, e.g., a 27 gauge needle lumen. The hydrogels of the present disclosure can be manufactured with the exact dimensions (ie, inner and outer diameters, and lengths) required to fit through the lumen of a needle of the desired gauge.
[0020] Polymer Backbone In certain embodiments, the material is a hydrogel comprising a polymer comprising a backbone in which the majority of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. As used herein, the term "secondary" carbon means a carbon atom that is bonded to two other carbon atoms and two other hydrogens. As used herein, the term "quaternary" carbon means a carbon atom that is bonded to four other carbon atoms and does not have a hydrogen. In certain embodiments, this arrangement of alternating quaternary and secondary carbon atoms promotes the stability of the polymer. In certain embodiments, the polymer backbone comprising alternating quaternary and secondary carbon atoms is resistant to oxidation, hydrolysis, or embrittlement in a biological environment. In certain embodiments, the polymer backbone comprising alternating quaternary and secondary carbon atoms does not oxidize, hydrolyze, or embrittle in a biological environment. In certain embodiments, the polymer is configured to minimize or prevent cracking, creasing, or degradation when implanted in vivo or otherwise exposed to degradative conditions.
[0021] In certain embodiments, the polymer comprises a backbone in which the majority of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 25% to about 100%, about 50% to about 100%, about 75% to about 100%, about 90% to about 100%, or about 95% to about 100% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 98% to about 100% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 95% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 97% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which about 99% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms. In certain embodiments, the polymer comprises a backbone in which more than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the polymer bonds along the polymer chain are alternating quaternary and secondary carbon atoms.
[0022] In certain embodiments, the material is a hydrogel comprising a polymer comprising a backbone in which the majority of the polymer bonds along the polymer chain are alternating tertiary and secondary carbon atoms. As used herein, the term "tertiary" carbon refers to a carbon atom that is bonded to three other carbon atoms and one hydrogen atom. Those skilled in the art will know that these polymers can support conjugated double bonds on their backbones, which can lead to biological instability, but in certain embodiments, the polymers are biologically stable. Thus, in certain embodiments, polymers in which the majority of the polymer bonds along the polymer chain are alternating tertiary and secondary carbon atoms are biologically stable.
[0023] In certain embodiments, the hydrogel comprises a non-degradable swellable polymer comprising a mixture of monomers including a swellable monomer and a hydrophobic monomer, hi certain embodiments, the hydrogel is formed from a mixture of monomers including both hydrophobic and swellable monomers.
[0024] Hydrophobic Monomers The term "hydrophobic monomer" as used herein means that the monomer, upon polymerization, substantially prevents water from penetrating the resulting polymer structure. In certain embodiments, the hydrophobic monomer is a non-swelling monomer. In certain embodiments, upon polymerization of the hydrophobic monomer, the resulting polymer is a non-swelling polymer. In certain embodiments, the hydrophobic monomer produces a polymer that substantially prevents water from penetrating the resulting polymer structure such that the polymer does not swell upon hydration. In certain embodiments, the hydrophobic monomer comprises a side group that comprises a hydrophobic group. In certain embodiments, the hydrophobic monomer comprises a side group that does not comprise a hydrophilic group. One skilled in the art will appreciate that a quaternary carbon on the polymer backbone comprises two side groups. In certain embodiments, both side groups on the quaternary carbon of the hydrophobic monomer comprise a hydrophobic group. In certain embodiments, the hydrophobic group is selected from the group consisting of alkyl, cycloalkyl, aryl, halo, alkylaryl, and alkoxy. In certain embodiments, the hydrophobic group is selected from the group consisting of C 1-12 Alkyl, C 1-10 Alkyl, C1-8 Alkyl, C 1-6 Alkyl, C 1-4 Alkyl, C 2-4 Alkyl, C 2-6 Alkyl, C 2-8 Alkyl, C 2-10 Alkyl 、 C 2-12 In certain embodiments, the hydrophobic group is selected from alkyl, methyl, ethyl, propyl, butyl, and hexyl, each of which may be linear, branched, or cyclic, each of which may be further substituted with an aryl group. In certain embodiments, the hydrophobic group is selected from methyl, ethyl, propyl, fluoro, and ethylbenzyl.
[0025] In certain embodiments, the hydrophobic monomer is an acrylate or an acrylamide. In certain embodiments, the hydrophobic monomer is an alkyl acrylate. In certain embodiments, the hydrophobic monomer is a haloacrylate. In certain embodiments, the hydrophobic monomer is an alkyl alkyl acrylate. In certain embodiments, the hydrophobic monomer is a haloalkyl acrylate. In certain embodiments, the hydrophobic monomer is an aryl alkyl acrylate. In certain embodiments, the hydrophobic monomer is a phenyl acrylate. In certain embodiments, the hydrophobic monomer is a methacrylate. In certain embodiments, the hydrophobic monomer is selected from methyl methacrylate, isobutyl methacrylate, butyl methacrylate, ethyl methacrylate, benzyl methacrylate, cyclohexyl methacrylate, 2-ethylhexyl methacrylate, hexadecyl methacrylate, hexyl methacrylate, octadecyl methacrylate, and 2-ethylphenyl acrylate. In certain embodiments, the hydrophobic monomer is methyl methacrylate (MMA).
[0026] Swelling Monomer As used herein, the term "swellable monomer" refers to a monomer that upon its polymerization has the ability to draw water into the resulting polymer. In certain embodiments, the swellable monomer comprises a side group that comprises a hydrophilic group. The hydrophilic group promotes swelling of the polymer by drawing water into the polymer. One skilled in the art will appreciate that the degree of swelling of the polymer depends on the hydrophilicity of the hydrophilic functional group on the monomer. One skilled in the art will appreciate that the quaternary carbon on the polymer backbone comprises two side groups. In certain embodiments, each side group of the quaternary carbon of the swellable monomer comprises a hydrophilic group. In certain embodiments, the swellable monomer comprises a quaternary carbon where one side group of the quaternary carbon comprises a hydrophilic group and one side group of the quaternary carbon comprises a hydrophobic group. In certain embodiments, the hydrophilic group is selected from the group consisting of hydroxyl, amino, carboxyl, sulfhydryl, carbonyl, amide, pyrrolidone, and anhydride. One skilled in the art will appreciate that any of the hydrophobic monomers having a side portion containing a hydrophobic group as described above can be modified (or functionalized) with one or more hydrophilic groups to produce a side portion containing a hydrophilic group. As a non-limiting example, the hydrophobic monomer ethyl methacrylate can be modified with a hydroxyl group to produce (hydroxyethyl) methacrylate, thereby forming a swellable monomer.
[0027] In certain embodiments, the swellable monomer is selected from hydroxy(C2-C4-alkyl)methacrylates, hydroxy(alkyl)acrylates, hydroxy(alkoxyalkyl)methacrylates, hydroxy(alkoxyalkyl)acrylates, alkoxy(alkoxyalkyl)methacrylates, alkoxy(alkoxyalkyl)acrylates, N-(alkyl)acrylamides, N-(alkyl)methacrylamides, N,N-di(alkyl)acrylamides, N,N-(di(alkyl))methacrylamides, vicinal-epoxy(C1-C4 alkyl)methacrylates, vicinal-epoxy(alkyl)acrylates, and alkyl acrylates. In certain embodiments, the alkyl group is selected from C 1-12 Alkyl, C 1-10 Alkyl, C 1-8 Alkyl, C1-6 Alkyl, C 1-4 Alkyl, C 2-4 Alkyl, C 2-6 Alkyl, C 2-8 Alkyl, C 2-10 Alkyl, C 2-12 In certain embodiments, the alkoxy group is selected from alkyl, methyl, ethyl, propyl, butyl, and hexyl, each of which may be linear or branched. 1-12 Alkoxy, C 1-10 Alkoxy, C 1-8 Alkoxy, C 1-6 Alkoxy, C 1-4 Alkoxy, C 2-4 Alkoxy, C 2-6 Alkoxy, C 2-8 Alkoxy 、 C 2-10 Alkoxy 、 C 2-12 It is selected from alkoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, and hydroxylhexyl, each of which can be linear or branched.
[0028] In certain embodiments, the swellable monomer is selected from hydroxy(C2-C4-alkyl)methacrylates, hydroxy(C2-C4 alkyl)acrylates, hydroxy(C2-C4 alkoxyC2-C4 alkyl)methacrylates, hydroxy(C2-C4 alkoxyC2-C4 alkyl)acrylates, alkoxy(C2-C4 alkoxyC2-C4 alkyl)methacrylates, alkoxy(C2-C4 alkoxyC2-C4 alkyl)acrylates, N-(C1-C4 alkyl)acrylamides, N-(C1-C4 alkyl)methacrylamides, N,N-di(C1-C4 alkyl)acrylamides, N,N-(di(C1-C4 alkyl))methacrylamides, vicinal-epoxy(C1-C4 alkyl)methacrylates, vicinal-epoxy(C1-C4 alkyl)acrylates, and (C1-C4 alkyl)acrylates.
[0029] In certain embodiments, the swelling monomer is 2-(hydroxyethyl)methacrylate (HEMA) (those skilled in the art will know that other synonyms of HEMA include, for example, (hydroxyethyl)methacrylate, 2-(hydroxyethyl)methacrylate, 2-hydroxyethylmethacrylate, hydroxyethylmethacrylate, and (hydroxyethyl)methacrylate), tetrahydrofurylmethacrylate, N,N-dimethylacrylamide, (2-hydroxypropyl)methacrylate (HPMA), methacrylamide, N-methylpyrrolidone, methacrylic acid (MAA), and the like. In certain embodiments, the swelling monomer is 2-(hydroxyethyl)methacrylate (HEMA). In certain embodiments, the swelling monomer is tetrahydrofurylmethacrylate. In certain embodiments, the swelling monomer is N,N-dimethylacrylamide. In certain embodiments, the swelling monomer is N-methylpyrrolidone. In certain embodiments, the swelling monomer is methacrylic acid (MAA).
[0030] In certain embodiments, the swelling monomer is a non-ionizable swelling monomer. As used herein, a non-ionizable swelling monomer is a swelling monomer that includes a non-ionizable hydrophilic side group, i.e., a hydrophilic side group that cannot be ionized. In certain embodiments, the non-ionizable hydrophilic side group is a side group that is hydrophilic but does not include an acid moiety. In certain embodiments, the non-ionizable swelling monomer is a monomer that is hydrophilic but does not include an acid moiety, i.e., any of the swelling monomers described above that does not include an acid moiety.
[0031] In certain embodiments, the swelling monomer is an ionizable or ionizable swelling monomer. As used herein, an ionizable swelling monomer is a swelling monomer that includes an ionizable side group, i.e., a side group that can be ionized. As used herein, an ionizable swelling monomer is a swelling monomer that includes a charged side group at neutral pH. In certain embodiments, an ionizable swelling monomer has a pK of, for example, about 3 to about 8.a Examples of ionizable or ionizable side groups include, but are not limited to, amines, ammonium salts, carboxylic acids, sulfonic acids, etc. In certain embodiments, the non-ionizable swellable monomer is a monomer that is hydrophilic and contains an acid moiety, i.e., any of the swellable monomers described above that contain an acid moiety.
[0032] Polymer structure and crosslinking agent Those skilled in the art will recognize that hydrogels are formed from high water content polymers that may contain physical or chemical crosslinks (i.e., bonds connecting one polymer chain to another) that result in a network structure. In certain embodiments, the polymer is a crosslinked linear polymer. In certain embodiments, the polymer is a crosslinked branched polymer. In certain embodiments, the polymer is a crosslinked star polymer.
[0033] In certain embodiments, the polymer is a block copolymer. In certain embodiments, the polymer is an alternating copolymer. In certain embodiments, the polymer is a periodic copolymer. In certain embodiments, the polymer is a random copolymer.
[0034] In certain embodiments, the hydrogel is formed from a low molecular weight polymer. In certain embodiments, the hydrogel is formed from a thermoplastic polymer. In certain embodiments, the hydrogel is formed from a polymer. In certain embodiments, the number average molecular weight (Mn) of the polymer forming the hydrogel is about 2 kDa to about 200 kDa, about 100 kDa to about 200 kDa, about 150 kDa to about 200 kDa, about 75 kDa to about 150 kDa, about 5 kDa to about 80 kDa, about 10 kDa to about 75 kDa, about 20 kDa to about 80 kDa, about 10 kDa to about 50 kDa, about 10 kDa to about 25 kDa, about 10 kDa to about 20 kDa, about 50 kDa to about 100 kDa, about 2 kDa to about 10 kDa, about 5 kDa to about 20 kDa, about 5 kDa to about 15 kDa, or about 2 kDa to about 10 kDa. In some embodiments, the number average molecular weight (Mn) of the low molecular weight polymer forming the hydrogel is about 2 kDa, about 5 kDa, about 8 kDa, or about 10 kDa.
[0035] In certain embodiments, the hydrogel is formed from a thermosetting polymer. In some embodiments, the thermosetting polymer has a number average molecular weight greater than about 200 kDa. Those skilled in the art will know that a thermosetting polymer can have an infinite molecular weight.
[0036] In certain embodiments, the polymer can have a degree of crosslinking of about 0 to about 1. In certain embodiments, the polymer can have a degree of crosslinking of about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 0.99. In certain embodiments, the polymer can be fully crosslinked (i.e., a degree of crosslinking of about 1).
[0037] In certain embodiments, hydrogels are formed from chemically crosslinked polymers. In certain embodiments, the equilibrium swelling time of a hydrogel is a function of crosslinker content. In certain embodiments, increasing crosslinker increases the equilibrium swelling time of a hydrogel (due to the reduced ability of water molecules to enter the hydrogel network and form bonds with hydrophilic groups, and the time it takes for disentanglement and swelling (entropy problem)).
[0038] In some embodiments, the crosslinker is a small molecule. In some embodiments, the crosslinker is a dimer. Examples of suitable crosslinkers include, but are not limited to, (tetraethylene glycol) dimethacrylate (TEGDMA), N,N'-methylenebis(acrylamide) (MBA), ethylene glycol diacrylate (EGDA) and PEG diacrylate (PEGDA), tetramethylethylenediamine (TEMED). Additional suitable crosslinkers are dimers of monomers selected from hydroxy(C2-C4-alkyl)methacrylates, hydroxy(C2-C4 alkyl)acrylates, hydroxy(C2-C4 alkoxyC2-C4 alkyl)methacrylates, hydroxy(C2-C4 alkoxyC2-C4 alkyl)acrylates, alkoxy(C2-C4 alkoxyC2-C4 alkyl)methacrylates, alkoxy(C2-C4 alkoxyC2-C4 alkyl)acrylates, N-(C1-C4 alkyl)acrylamides, N-(C1-C4 alkyl)methacrylamides, N,N-di(C1-C4 alkyl)acrylamides, N,N-(di(C1-C4 alkyl))methacrylamides, vicinal-epoxy(C1-C4 alkyl)methacrylates, and vicinal-epoxy(C1-C4 alkyl)acrylates. In certain embodiments, the hydrogel is formed from a solution in which the crosslinker is present in a ratio of crosslinker weight to polymer weight that is about 0.01% to about 1%, about 0.01% to about 0.9%, about 0.01% to about 0.8%, about 0.01% to about 0.7%, about 0.01% to about 0.6%, about 0.01% to about 0.5%, about 0.01% to about 0.4%, about 0.01% to about 0.3%, about 0.01% to about 0.2%, or about 0.01% to about 0.1%. In certain embodiments, the hydrogel is formed from a solution in which the crosslinker is present in an amount of about 0.01%, about 0.02%, about 0.03%, about 0.06%, about 0.09%, about 0.12%, about 0.15%, about 0.18%, about 0.21%, about 0.24%, about 0.27%, or about 0.3%.
[0039] Hydrogel Materials In certain embodiments, the materials disclosed herein are hydrogels formed from the polymerization of the monomers described above. One skilled in the art will know that when a hydrogel comes into contact with water, absorption of water molecules into the hydrogel matrix occurs. In certain embodiments, the material swells as a function of hydration (e.g., as a function of exposure to water in a biological location). In certain embodiments, the degree of swelling depends on the ratio of hydrophilic and hydrophobic side groups present in the hydrogel. In certain embodiments, the degree of swelling will depend on the ratio of one or more different hydrophilic side groups in the hydrogel. In certain embodiments, the degree of swelling will depend on the ratio of one or more different hydrophilic side groups to a plurality of one or more different hydrophobic side groups. In certain embodiments, the degree of swelling will depend on the ratio of hydrophobic monomers to swelling monomers in the hydrogel. In certain embodiments, the hydrogel is formed from the copolymerization of one hydrophobic monomer and one swelling monomer, such as, by way of non-limiting example, the polymerization of 2-(hydroxyethyl) methacrylate and methyl methacrylate. In certain embodiments, the hydrogel is formed from the copolymerization of a non-ionizable swelling monomer with an ionizable or ionizable swelling monomer. One skilled in the art will recognize that the non-ionizable and ionizable swelling monomers have side groups that contain hydrophilic functional groups to varying degrees. As a non-limiting example, the hydrogel can be formed from the copolymerization of 2-(hydroxyethyl)methacrylate (a non-ionizable swelling monomer) with methacrylic acid (an ionizable swelling monomer). Because methacrylic acid has an ionizable carboxylic acid group, even a small amount of methacrylic acid in the resulting hydrogel results in a large amount of swelling.
[0040] In certain embodiments, the hydrogel comprises about 1% to about 100%, about 1% to about 90%, about 1% to about 80%, about 1% to about 70%, about 1% to about 60%, about 1% to about 50%, about 1% to about 40%, about 1% to about 30%, about 1% to about 20%, or about 1% to about 10% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, or about 5% to about 10% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, or about 20% to about 30% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, or about 30% to about 40% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, or about 40% to about 50% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, or about 50% to about 60% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, or about 60% to about 70% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 70% to about 100%, about 70% to about 90%, or about 70% to about 80% of side groups comprising hydrophobic groups. In certain embodiments, the hydrogel comprises about 80% to about 100%, about 80% to about 90%, or about 0% to about 100% of side groups comprising hydrophobic groups.
[0041] In certain embodiments, the hydrogel comprises about 1% to about 100%, about 1% to about 90%, about 1% to about 80%, about 1% to about 70%, about 1% to about 60%, about 1% to about 50%, about 1% to about 40%, about 1% to about 30%, about 1% to about 20%, or about 1% to about 10% of side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, or about 5% to about 10% of side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, or about 20% to about 30% of side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, or about 30% to about 40% of side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, or about 40% to about 50% side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, or about 50% to about 60% side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, or about 60% to about 70% side groups comprising new hydrophilic groups. In certain embodiments, the hydrogel comprises about 70% to about 100%, about 70% to about 90%, or about 70% to about 80% side groups that comprise new hydrophilic groups. In certain embodiments, the hydrogel comprises about 80% to about 100%, about 80% to about 90%, or about 90% to about 100% side groups that comprise new hydrophilic groups.
[0042] In certain embodiments, the hydrogel comprises about 1% to about 100%, about 1% to about 90%, about 1% to about 80%, about 1% to about 70%, about 1% to about 60%, about 1% to about 50%, about 1% to about 40%, about 1% to about 30%, about 1% to about 20%, or about 1% to about 10% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, or about 5% to about 10% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, or about 20% to about 30% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, or about 30% to about 40% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, or about 40% to about 50% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, or about 50% to about 60% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, or about 60% to about 70% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 70% to about 100%, about 70% to about 90%, or about 70% to about 80% ionized or ionizable side groups. In certain embodiments, the hydrogel comprises about 80% to about 100%, about 80% to about 90%, or about 90% to about 100% ionized or ionizable side groups.
[0043] In certain embodiments, the hydrogel comprises a polymer with a ratio of hydrophobic monomers to swelling monomers of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50. In certain embodiments, the hydrogel comprises a polymer with a ratio of swelling monomers to hydrophobic monomers of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50.
[0044] In certain embodiments, the hydrogel comprises a polymer formed from a non-ionizable swellable monomer and an ionizable or ionizable swellable monomer, the ionizable or ionizable swellable monomer having a greater swelling capacity than the non-ionizable swellable monomer, hi certain embodiments, the hydrogel comprises a polymer having a ratio of non-ionizable swellable monomer to ionizable or ionizable swellable monomer of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50. In certain embodiments, the hydrogel comprises a polymer having a ratio of ionized or ionizable swellable monomers to non-ionizable swellable monomers of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50.
[0045] In certain embodiments, the hydrogel comprises a polymer formed from two swellable monomers, the first swellable monomer having a greater swelling capacity than the second swellable monomer, hi certain embodiments, the hydrogel comprises a polymer having a ratio of the first swellable monomer to the second swellable monomer of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50. In certain embodiments, the hydrogel comprises a polymer having a ratio of the second swellable monomer to the first swellable monomer of about 99.09:0.01, 99.9:0.1, 99.5:0.5, 98:2, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, or 50:50.
[0046] In certain embodiments, the hydrogel is composed of multiple, e.g., two or more, different types of monomers, each containing side groups with various degrees of swelling. For example, in certain embodiments, the hydrogel comprises a polymer formed from a hydrophobic monomer, a non-ionizable monomer, and an ionizable or ionizable monomer. In certain embodiments, the hydrogel comprises a polymer formed from one or more hydrophobic monomers, one or more non-ionizable monomers, and one or more ionizable or ionizable monomers. In certain embodiments, the hydrogel comprises a polymer formed from one or more hydrophobic monomers, one or more non-ionizable monomers, and one or more ionizable or ionizable monomers, or combinations thereof. The ratio of the different monomers (and ultimately the relative contribution of the various hydrophilic groups) depends on the degree of swelling of the material. As a non-limiting example, a glaucoma shunt may require the shunt to swell 100% upon hydration, e.g., upon placement in the eye. Those skilled in the art will understand that different degrees of swelling are desired for the device depending on the type of device made with the disclosed hydrogels.
[0047] In certain embodiments, the hydrogel may comprise a polymer of the following general formula:
[0048] TIFF0007584452000002.tif3168 where R and R″ are, independently at each occurrence, a hydrophobic side group; R′ is selected from a hydrophobic side group, an ionizable or ionizable side group, or a non-ionizable hydrophilic side group; and R′″ is selected from an ionizable or ionizable side group, or a non-ionizable hydrophilic side group.
[0049] In certain embodiments, R and R″ each independently comprise a hydrophobic group, R′ comprises a group selected from a hydrophobic group, an ionizable or ionizable group, or a non-ionizable hydrophilic group, and R′″ comprises a group selected from an ionizable or ionizable group, or a non-ionizable hydrophilic group.
[0050] In certain embodiments, R and R″ each independently comprise a hydrophobic end group, R′ comprises an end group selected from a hydrophobic group, an ionizable or ionizable group, or a non-ionizable hydrophilic group, and R′″ comprises an end group selected from an ionizable or ionizable group, or a non-ionizable hydrophilic group.
[0051] In certain embodiments, R, R', and R'' are, independently at each occurrence, hydrophobic side groups and R''' is an ionized or ionizable group, or a non-ionizable hydrophilic group.
[0052] In certain embodiments, R, R', and R'' each independently comprise a hydrophobic group selected from alkyl, aryl, halo, alkylaryl, and alkoxy, and R''' comprises a hydrophilic group selected from the group consisting of hydroxyl, amino, carboxyl, sulfhydryl, carbonyl, amide, and anhydride.
[0053] In certain embodiments, R, R', and R'' each independently comprise a hydrophobic end group selected from alkyl, aryl, halo, alkylaryl, and alkoxy, and R''' comprises a hydrophilic end group selected from the group consisting of hydroxyl, amino, carboxyl, sulfhydryl, carbonyl, amide, and anhydride.
[0054] In certain embodiments, R and R″, independently at each occurrence, are hydrophobic side groups and R′ and R′″ are selected from non-ionizable hydrophilic side groups and ionizable or ionizable side groups. In certain embodiments, R and R″, independently at each occurrence, are hydrophobic side groups, R′ is a non-ionizable hydrophilic side group and R′″ is an ionizable or ionizable side group. In certain embodiments, R′″ is selected from amines, ammonium salts, carboxylic acids, and sulfonic acids.
[0055] In certain embodiments, R' and R''' are -COOR 1 or -CONR 1 R 2 R' is selected from alkyl, aryl, halo, alkylaryl, and alkoxy; R 1 is independently selected at each occurrence from alkyl, aryl, and alkylaryl; R 2 is selected from hydrogen, alkyl, aryl, and alkylaryl.
[0056] In certain embodiments, the ratio of m:n is about 99.99:0.01 to about 90:10. In certain embodiments, the ratio of m:n is about 99:1. In certain embodiments, the ratio of m:n is about 98:2. In certain embodiments, the ratio of m:n is about 97:3. In certain embodiments, the ratio of m:n is about 96:4. In certain embodiments, the ratio of m:n is about 95:5. In certain embodiments, the ratio of m:n is about 94:6. In certain embodiments, the ratio of m:n is about 93:7. In certain embodiments, the ratio of m:n is about 92:8. In certain embodiments, the ratio of m:n is about 91:9. In certain embodiments, the ratio of m:n is about 90:10.
[0057] In certain embodiments, the polymer has the formula:
[0058] TIFF0007584452000003.tif4251 wherein the ratio of n:m is about 99:1. In certain embodiments, the ratio of m:n is about 98:2. In certain embodiments, the ratio of m:n is about 97:3. In certain embodiments, the ratio of m:n is about 96:4. In certain embodiments, the ratio of m:n is about 95:5. In certain embodiments, the ratio of m:n is about 94:6. In certain embodiments, the ratio of m:n is about 93:7. In certain embodiments, the ratio of m:n is about 92:8. In certain embodiments, the ratio of m:n is about 91:9. In certain embodiments, the ratio of m:n is about 90:10.
[0059] In certain embodiments, the polymer has the formula: TIFF0007584452000004.tif4251, wherein the ratio of m:n is 99.99:0.01. In certain embodiments, the ratio of m:n is about 99.9:0.1. In certain embodiments, the ratio of m:n is about 99.5:0.5. In certain embodiments, the ratio of m:n is about 99:1. In certain embodiments, the ratio of m:n is about 98:2. In certain embodiments, the ratio of m:n is about 97:3. In certain embodiments, the ratio of m:n is about 96:4. In certain embodiments, the ratio of m:n is about 95:5. In certain embodiments, the ratio of m:n is about 94:6. In certain embodiments, the ratio of m:n is about 93:7. In certain embodiments, the ratio of m:n is about 92:8. In certain embodiments, the ratio of m:n is about 91:9. In certain embodiments, the ratio of m:n is about 90:10.
[0060] How to make the polymer Polymer hydrogels can be formed from a variety of methods, including, but not limited to, free radical polymerization and crosslinking. The free radical addition reaction includes an initiator, a solvent, a crosslinker (as described above), and a monomer (as described above). The initiator can be any free radical initiator, such as a thermal initiator, a photoinitiator, or a redox initiator. Thermal initiators can include, for example, azo compounds such as 2,2'-azobis(isobutyronitrile) (AIBN), organic peroxides such as benzoyl peroxide (BPO), benzenesulfonic acid esters, alkylsulfonium salts, and the like. Certain redox free radical polymerizations can be carried out under aqueous conditions or in the presence of other solvents such as glycerin, ethylene glycol, aliphatic glycols, formic acid, acetic acid, and acetone. Redox initiators used under these conditions include peroxides, persulfates, peroxomonosulfates, and peroxyphosphates, such as sodium metabisulfite / ammonium peroxydisulfate.
[0061] In some embodiments, hydrogels are synthesized by combining an oxygen-purged aqueous solution of free radical initiator, solvent, and crosslinker with two or more monomers having various degrees of swelling properties, and then polymerizing the reaction for a period of time, e.g., overnight, under ambient pressure and temperature, at elevated temperature and / or at elevated pressure, or at reduced temperature and pressure. In some embodiments, the pressure is increased, e.g., to 100 psi.
[0062] In certain embodiments, the polymer hydrogel is formed by a redox free radical addition reaction involving aqueous sodium metabisulfite / ammonium peroxydisulfate solution as a redox free radical initiator, ethylene glycol as a solvent or co-solvent with water, and TEGDMA as a crosslinker.
[0063] device In certain embodiments, the hydrogels disclosed herein can be used in medical devices where it is desirable for them to swell when placed in a biological environment, including, but not limited to, intraocular devices such as intraocular shunts or glaucoma shunts.
[0064] Certain devices, e.g., tubular shunts, can be polymerized in a container such as a tube with a concentric mandrel such that when demolded, the removed mandrel forms a tube, In some embodiments, the tubular device can then be extracted with a solvent, e.g., water, isopropyl alcohol, tetrahydrofuran, and the like.
[0065] In certain embodiments, the device can be made by casting into a mold with a mandrel. In certain embodiments, a hydrogel formed from a thermosetting polymer can be used to make the device by casting into a mold with a mandrel. In certain embodiments, a hydrogel formed from a thermoplastic polymer can be used to make the device by casting into a mold with a mandrel. In certain embodiments, the device can be made by an extrusion process. In certain embodiments, a hydrogel formed from a thermoplastic polymer with a low degree of crosslinking can be used to make the device by an extrusion process. In certain embodiments, the device can be made using an air mandrel. In certain embodiments, the lumen of the device can be made using a wire where a polymer is extruded onto the wire to form the lumen. In certain embodiments, a hydrogel formed from a thermosetting crosslinked polymer can be used to make the device by an extrusion process. In certain embodiments, a piston cylinder can be used to make the device. In certain embodiments, the device can be manufactured as a rod with holes drilled concentrically into the rod to form a tube.
[0066] In certain embodiments, the device can be dried in the presence of a plasticizer, which can be any biocompatible fluid, such as glycerin, ethylene glycol, etc. In some embodiments, the biocompatible fluid plasticizer can be added to prevent cracking and facilitate rehydration. Thus, in some embodiments, the device material further comprises a plasticizer. In certain embodiments, the device can be contacted with 10% glycerin in 90% water (by weight) such that the glycerin plasticizes the device, and then the device can be dried to remove the water.
[0067] In some embodiments, the device has a diameter in a dehydrated state and a diameter in a hydrated state, the diameter in the dehydrated state being smaller than the diameter in the hydrated state. In some embodiments, the diameter of the device increases upon hydration of the device from the dehydrated state to the hydrated state. In some embodiments, the diameter increases by about 10% to about 500%, about 20% to about 400%, about 10% to about 300%, about 20% to about 300%, about 25% to about 250%, about 20% to about 100%, about 50% to about 150%, about 50% to about 100%, about 75% to about 100%, about 80% to about 100%, about 90% to about 110%, or about 100% to about 150% upon hydration. In some embodiments, the diameter increases by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, or about 200% upon hydration, hi certain embodiments, the diameter increases by about 100% upon hydration.
[0068] In certain embodiments, when the device is in a dehydrated state, the device is configured to fit into the lumen of a needle having a particular diameter. As used herein, the "gauge number" of a needle refers to the Birmingham gauge wire gauge system, which defines thickness and / or diameter for hypodermic needles and tubing products. In certain embodiments, when in a dehydrated state, the device is configured to fit into the lumen of a needle having a gauge number of 20 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, or 30 or more. In certain embodiments, when in a dehydrated state, the device is configured to fit into the lumen of a 23 gauge needle. In certain embodiments, when in a dehydrated state, the device is configured to fit into the lumen of a 27 gauge needle.
[0069] In certain embodiments, the device comprises an inner diameter and an outer diameter. In certain embodiments, the inner diameter of the device is the diameter of the lumen. In certain embodiments, the outer diameter of the device is the diameter of the outer wall of the device.
[0070] In certain embodiments, when the device is in a dehydrated state, the outer diameter of the device is about 100 μm to about 500 μm, about 200 μm to about 400 μm, about 100 μm to about 300 μm, about 200 μm to about 350 μm, about 125 μm to about 175 μm, about 125 μm to about 150 μm, about 150 μm to about 175 μm, about 140 μm to about 160 μm, or about 145 μm to about 155 μm. In certain embodiments, when the device is in a dehydrated state, the outer diameter of the device is about 150 μm. In certain embodiments, the outer diameter of the device in a dehydrated state is about 200 μm.
[0071] In certain embodiments, when the device is in a hydrated state, the outer diameter of the device is about 120 μm to about 750 μm, about 240 μm to about 600 μm, about 120 μm to about 450 μm, about 240 μm to about 525 μm, about 150 μm to about 275 μm, about 125 μm to about 150 μm, about 150 μm to about 175 μm, about 140 μm to about 160 μm, about 500 μm to about 700 μm, about 400 μm to about 500 μm, about 300 μm to about 500 μm, about 300 μm to about 400 μm, or about 145 μm to about 155 μm. In some embodiments, when the device is in a hydrated state, the outer diameter of the device is about 180 μm. In certain embodiments, when the device is in a hydrated state, the outer diameter of the device is about 225 μm. In certain embodiments, the outer diameter of the device is about 240 μm when the device is in a hydrated state. In certain embodiments, the outer diameter of the device is about 300 μm when the device is in a hydrated state.
[0072] In certain embodiments, when the device is in a dehydrated state, the inner diameter of the device is about 20 μm to about 120 μm, about 20 μm to about 75 μm, about 20 μm to about 50 μm, about 30 μm to about 75 μm, about 30 μm to about 60 μm, or about 40 μm to about 50 μm. In certain embodiments, when the device is in a dehydrated state, the inner diameter of the device is about 50 μm.
[0073] In certain embodiments, when the device is in a hydrated state, the inner diameter of the device is about 120 μm to about 250 μm, 150 μm to about 250 μm, 175 μm to about 250 μm, 150 μm to about 200 μm, 175 μm to about 225 μm, or 175 μm to about 200 μm. In certain embodiments, when the device is in a hydrated state, the inner diameter of the device is about 200 μm.
[0074] In certain embodiments, the device has a length in a dehydrated state and a length in a hydrated state, the length in the hydrated state being greater than the length in the dehydrated state. In some embodiments, the length of the device in the dehydrated state is about 3 mm to about 10 mm, 4 mm to about 10 mm, 5 mm to about 10 mm, 5 mm to about 8 mm, or 4 mm to 9 mm. In some embodiments, the length of the device in the dehydrated state is about 6 mm.
[0075] In certain embodiments, the length of the device in a hydrated state is about 3.5 mm to about 20 mm, about 5 mm to about 20 mm, about 8 mm to about 18 mm, or about 10 mm to about 20 mm. In certain embodiments, the length of the device in a hydrated state is about 12 mm.
[0076] Turning to the figures, FIG. 1A illustrates an intraocular tubular shunt 100a in a dehydrated state, including a lumen 120a extending along the length of the tubular shunt 100a. In certain embodiments, the outer diameter of the tubular shunt 100a is configured to fit into the lumen of a needle of a required gauge. FIG. 1B illustrates an intraocular tubular shunt 100b in a hydrated state, in which the lumen 120b, length, and outer diameter of the tubular shunt 100b are larger than the intraocular tubular shunt 100a depicted in FIG. 1A in a dehydrated state. FIG. 2 illustrates an intraocular tubular shunt 200 inserted into the lumen 220 of a needle 230. An inserter (not shown) for the intraocular tubular shunt 200 can be placed into the needle 230 for insertion into a patient's eye, and a plunger (not shown) behind the shunt 200 can be held in place within the needle 230 as it is inserted through tissue. FIG. 3 shows an intraocular tubular shunt 300 placed within hydrated tissue 310. As shown in FIG. 3, a needle (as shown in FIG. 2) is used to penetrate tissue 310 and a dehydrated tubular shunt (e.g., as shown in FIG. 1) is deployed across tissue 310. The plunger used to hold the shunt in place in the needle is held steady and the needle is withdrawn, leaving shunt 300 in place. Once hydrated, the end of needle 320b can expand to lock it in place. Similarly, the body of tube 300a can expand to seal the needle tract.
[0077] method Provided herein are methods of treating ocular diseases, such as glaucoma, comprising implanting various devices disclosed herein. For example, provided herein are methods of treating ocular diseases, comprising introducing or implanting an intraocular shunt made from the non-degradable swellable hydrogels disclosed herein into a subject in need thereof. In certain embodiments, the ocular disease is glaucoma. In certain embodiments, the ocular disease is ocular hypertension.
[0078] Provided herein is a method of implanting an ophthalmic device into a subject's eye. In certain embodiments, the ophthalmic device is a tubular drainage device, e.g., an intraocular tubular shunt. In certain embodiments, the shunt is implanted with one end in the anterior chamber of the eye. In certain embodiments, the shunt is loaded into the lumen of a needle (e.g., a 22-gauge to 30-gauge needle). In certain embodiments, a plunger is inserted into the proximal lumen of the device. In certain embodiments, the tip of the needle is inserted into the anterior chamber of the eye, and while the plunger is held steady, the needle is withdrawn, thereby leaving the shunt in place with the distal end (the end furthest from the user) in the anterior chamber of the eye. In certain embodiments, the proximal end of the shunt can be placed between the sclera and the conjunctiva or Tenon's capsule of the eye. In certain embodiments, the intraocular shunt can be placed with one end in the anterior chamber and the other end in Schlemm's canal, or in the suprachoroidal space, or transconjunctivally, or transcorneally, to drain outside the eye. In certain embodiments, the ocular shunt can be used to shunt aqueous humor from the anterior chamber to any outlet. In certain embodiments, the ocular shunt can shunt from the anterior chamber to Schlemm's canal. In certain embodiments, the ocular shunt can shunt from the anterior chamber to the suprachoroidal space. In certain embodiments, the ocular shunt can shunt from the anterior chamber to the bleb. In certain embodiments, the ocular shunt can shunt from the anterior chamber through the conjunctiva. In certain embodiments, the ocular shunt can shunt from the anterior chamber through the cornea. In certain embodiments, the ocular shunt can shunt from the anterior chamber through the conjunctiva to the outside of the eye. In certain embodiments, the ocular shunt can shunt from the anterior chamber through the cornea to the outside of the eye.
[0079] In certain embodiments, provided herein is a method of implanting an ocular shunt in an eye of a subject, comprising inserting a tip of a needle into the anterior chamber of the eye of the subject, the lumen of the needle containing the intraocular shunt, and removing the needle from the eye such that the intraocular shunt remains in the eye. In certain embodiments, the needle comprises a plunger proximal to the intraocular shunt. In certain embodiments, the plunger is removably coupled to the needle, e.g., within the lumen of the needle. In certain embodiments, the intraocular shunt is removably coupled to the needle, e.g., within the lumen of the needle. In certain embodiments, the method comprises loading the shunt into the lumen of the needle. In certain embodiments, the shunt implanted in the eye is made from a material as disclosed herein.
[0080] In certain embodiments, provided herein is a method of treating glaucoma or ocular hypertension in a subject in need thereof, comprising: introducing into the eye of the subject an intraocular shunt formed from a material including a polymer; The polymer is: a first monomer comprising a first side group; a second monomer comprising a second side group; and Crosslinking agent; is formed from the reaction product of the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group; and A method is provided in which the intraocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0081] In certain embodiments, provided herein is the use of an intraocular shunt for treating glaucoma or ocular hypertension, comprising: the intraocular shunt is formed from a material including a polymer; The polymer is: a first monomer comprising a first side group; a second monomer comprising a second side group; and Crosslinking agent; is formed from the reaction product of the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group; and Use is provided in which the intraocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0082] In certain embodiments, provided herein is the use of an intraocular shunt for implantation in a subject in need thereof, comprising: the intraocular shunt is formed from a material including a polymer; The polymer is: a first monomer comprising a first side group; a second monomer comprising a second side group; and Crosslinking agent; is formed from the reaction product of the hydrophilicity of the second side group is greater than the hydrophilicity of the first side group; and Use is provided in which the intraocular shunt has a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
[0083] When values or ranges are provided herein, it is to be understood that all values or ranges subsumed within those values or ranges are meant to be encompassed within the scope of the present application. Moreover, all values that fall within those ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
[0084] The following examples further illustrate aspects of the present application, but do not in any way limit the teachings or disclosure set forth herein.
[0085] Working Example Example 1: Synthesis of poly((2-hydroxyethyl)methacrylate) / methacrylic acid hydrogel
[0086] procedure. All percentages are by weight.
[0087] Solution A was 0.044 M ammonium peroxydisulfate dissolved in deionized water (2 g / 100 mL water); solution B was 0.0420 M sodium metabisulfite dissolved in water (4.0 g / 100 mL water); solutions A and B were purged of oxygen by bubbling nitrogen through them for 10 min.
[0088] Hydrogels were made by combining the following: 60% purified 2-(hydroxyethyl) methacrylate (HEMA) monomer; 0.2% TEGDMA; varying amounts (0%, 1%, 2%, 3%, or 4%) of methacrylic acid (MAA); 20% ethylene glycol; 10% solution A; and 10% solution B.
[0089] All components of the reaction mixture were mixed thoroughly. The reaction mixture was polymerized overnight under 100 psi pressure, forming a homogeneous gel.
[0090] The hydrogel was polymerized in a 10 mL syringe by pressurizing the contents of the syringe with a weight on the plunger. The solvent was 20% ethylene glycol and 20% water (from parts A and B). It was removed from the syringe and allowed to hydrate for several days to remove impurities.
[0091] result
[0092] The swelling percentage of the hydrogels in saline was a function of the amount of methacrylic acid (MAA) present in the reaction mixture and therefore in the resulting hydrogel. Figure 4 shows the results of Example 1. Specifically, Figure 4 shows the water content and swelling volume of gels with various mole % of ionizable monomer methacrylic acid (MAA) versus the mole % of crosslinker (TEGDMA) in the gel. The base polymer (formed from non-ionizable monomers) is poly(2-hydroethyl methacrylate). The swelling ratio was determined by weighing the polymer before and after swelling. Since 1 mL of water weighs 1 g, the volume change is directly proportional to the weight change.
[0093] Example 2: Casting a swellable pHEMA formulation in a pressurized syringe
[0094] material In Example 2, the following materials were used: (1) Ammonium peroxydisulfate (Sigma-Aldrich 248614-100g); Sodium metabisulfite (Sigma-Aldrich S9000-500g); Methacrylic acid (MAA) (Sigma-Aldrich 155721-500g); triethylene glycol dimethacrylate (TEGDMA) (Sigma-Aldrich 759406-10mL); Ethylene glycol (EG) (Sigma-Aldrich 324558); and 2-Hydroxyethyl methacrylate (HEMA) (Polyscience 04675-100)
[0095] procedure Ammonium peroxydisulfate solution was prepared by dissolving 2 g of ammonium peroxydisulfate in 100 mL of deionized water and bubbling nitrogen through the solution for five (5) minutes to purge dissolved oxygen. Sodium metabisulfite solution was prepared by dissolving 4 g of sodium metabisulfite in 100 mL of deionized water and bubbling nitrogen through the solution for five (5) minutes to remove dissolved oxygen. 6 mL of HEMA, 0.24 mL of MMA, 0.04 mL of TEGDMA, and 2 mL of EG were mixed in a 10 mL polypropylene syringe and then bubbling nitrogen through the solution for five (5) minutes to remove dissolved oxygen. Next, 1 mL of the prepared ammonium peroxydisulfate solution and 1 mL of the prepared sodium metabisulfite solution were added to the 10 mL syringe. The syringe was then shaken to create a homogenous solution. The syringe was then kept pressurized overnight at room temperature by depressing the syringe plunger using a syringe pump, and the solution was allowed to polymerize overnight. The polymerized pHEMA was then removed from the syringe and cut into disks for swelling tests.
[0096] Swelling test The pHEMA samples from the syringe were incubated in deionized water (DI), phosphate buffered saline (PBS (pH 7.4)), pH 10 solution, and pH 4 solution for 48 hours, and their swelling weights were measured, and then they were vacuum dried to a constant weight. The weight changes are shown in Table 1. TIFF0007584452000005.tif39155
[0097] Example 3: Preparation of swellable pHEMA tubes by casting
[0098] The same formulation of Example 2 was used to prepare swellable tubes by casting in a mold with a mandrel. Figure 5 (top) shows the tube after 1 hour incubation in DI water. Figure 5 (bottom) shows the tube after 1 hour incubation in DI water and vacuum drying to constant weight.
[0099] Example 4: Preparation of swellable pHEMA tubes by extrusion
[0100] procedure 0.22 g of azobisisobutyronitrile (AIBN), 5.24 g of 2-hydroxyethyl methacrylate (HEMA), and 1.17 g of methacrylic acid (MA) were mixed in a 20 mL vial and polymerized overnight. The resulting pHEMA was dissolved in dimethylformamide (DMF) and compression moldable at 200 °C. Tubes were extruded using a plunge extruder.
[0101] Example 5: Creation of a Glaucoma Shunt
[0102] Glaucoma shunts are made using the formulations and methods of Examples 1-4 above. The shunts are made to dimensions that allow the shunt to be used with a 27 gauge needle. The shunts are manufactured with a dehydrated outer diameter of about 200 μm, a dehydrated inner diameter of about 50 μm, and a dehydrated length of about 6 μm. The shunts are incubated in water to a dehydrated outer diameter of about 300 μm, a dehydrated inner diameter of about 200 μm, and a dehydrated length of about 12 μm.
[0103] Example 6: Treatment of Glaucoma
[0104] A shunt made using the formulations and methods of Examples 1-5 is implanted into a patient suffering from glaucoma. The shunt is implanted using a 27 gauge needle. The shunt is effective in treating glaucoma. The patient shows reduced pressure on the optic nerve, reduced eye damage, and / or reduced vision loss, or slower progression of glaucoma symptoms compared to untreated patients or patients treated with known devices.
[0105] Example 6: Treatment of Ocular Hypertension
[0106] A shunt made using the formulations and methods of Examples 1-5 is implanted into a patient suffering from ocular hypertension. The shunt is implanted using a 27 gauge needle. The shunt is effective in treating ocular hypertension. Fluids such as aqueous humor are redirected and the patient exhibits a reduction in intraocular pressure. The patient exhibits reduced pressure on the optic nerve, reduced eye damage, and / or reduced vision loss compared to untreated patients or patients treated with known devices.
Claims
1. The following formula:
1. An intraocular shunt formed from a material comprising a non-degradable swellable polymer having R and R″ are methyl; R' is -COOR 1 where R 1 is alkyl; R''' is a carboxylic acid; The ratio of m:n is 99.99:0.01 to 90:10; An intraocular shunt, the intraocular shunt having a first diameter in a dehydrated state and a second diameter in a hydrated state, the second diameter being greater than the first diameter.
2. 10. The intraocular shunt of claim 1, which increases in diameter by 20% to 200% upon hydration.
3. 3. The intraocular shunt of claim 1, which increases in diameter by 50% to 100% upon hydration.
4. The intraocular shunt of any one of claims 1 to 3, which increases in diameter by 100% upon hydration.
5. An intraocular shunt as described in any one of claims 1 to 4 for use in a method for treating glaucoma or ocular hypertension in a subject in need of such treatment, comprising introducing or implanting an intraocular shunt into the eye of the subject.
Citation Information
Patent Citations
Ocular implant with intraocular fluid pressure regulation
WO2013069018A2
